"Today's update on the annual evaluation of adverse event reports associated with Essure is part of the FDA's continuing commitment to regularly communicate with patients and health care providers to provide up-to-date information about this permanent birth control device. Even though this device is no longer sold or being implanted in women, our work to continually monitor the long-term safety profile of Essure is part of our broader effort to assure device safety, which includes ongoing post-market surveillance of safety concerns even after a device is removed from the market."